publication . Article . 2004

Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention: The randomized, double-blind, placebo-controlled, multicenter verapamil slow-release for prevention of cardiovascular events after angioplasty (VESPA) trial ☆

Bestehorn, Hans-Peter; Neumann, Franz-Josef; Büttner, Heinz Joachim; Betz, Peter; Stürzenhofecker, Peter; von Hodenberg, Eberhard; Verdun, Antoine; Levai, Laszlo; Monassier, Jean Pierre; Roskamm, Helmut;
Open Access
  • Published: 01 Jun 2004 Journal: Journal of the American College of Cardiology, volume 43, pages 2,160-2,165 (issn: 0735-1097, Copyright policy)
  • Publisher: Elsevier BV
Abstract
Abstract Objectives We investigated the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention (PCI). Background Thus far, there is no established systemic pharmacologic approach for the prevention of restenosis after PCIs. Five small studies reported encouraging results for calcium channel blockers. Methods Our randomized double-blind trial included 700 consecutive patients with successful PCI of a native coronary artery. Patients received the calcium channel blocker verapamil, 240 mg twice daily for six months, or placebo. Primary clinical end point was the composite rate of death, myocardial infarctio...
Subjects
free text keywords: Antiarrhythmic agent, medicine.medical_treatment, medicine, Internal medicine, medicine.medical_specialty, Verapamil, medicine.drug, Angioplasty, Restenosis, medicine.disease, Cardiology, Conventional PCI, business.industry, business, Percutaneous coronary intervention, Myocardial infarction, Anesthesia, Placebo, Cardiology and Cardiovascular Medicine
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue